Pyrazoloquinazoline Kinase Inhibitors for Selective CDK Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK inhibitors have limitations in terms of selectivity and efficacy for treating cancer and other cell proliferative diseases, with a need for compounds with improved pharmacokinetic properties and broader inhibitory activity.
Innovation Solution
Development of 1H-pyrazolo[4,3-H]quinazoline compounds that act as broad-spectrum inhibitors of cyclin-dependent kinase (CDK), offering enhanced metabolic stability and versatility in administration methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CDK inhibitors are used, then they can inhibit CDK activity, but they have limited selectivity and poor pharmacokinetic properties
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the pyrazoloquinazoline core structure. Different substituents (R1-R6) are placed at specific locations to optimize interactions with different CDK isoforms, thereby achieving selective inhibition while maintaining overall inhibitory activity
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, molecular weight, lipophilicity, and hydrogen bonding capacity. These parameter optimizations improve both the selectivity and pharmacokinetic properties while preserving the core inhibitory function against CDK
2Reliability
If existing CDK inhibitors are used, then they can treat cell proliferative diseases, but they have poor metabolic stability and clearance rate
Solution Approach 1:
The patent optimizes metabolic stability by adjusting chemical parameters including introducing metabolically stable substituent groups, avoiding labile functional groups, and tuning molecular properties to resist enzymatic degradation. This extends half-life and improves pharmacokinetic profile while maintaining therapeutic efficacy
Solution Approach 2:
The patent uses composite material principles by combining the pyrazoloquinazoline core with various stabilizing substituents and protective groups. This creates a composite molecular structure that resists metabolic breakdown while preserving the active pharmacophore necessary for CDK inhibition
3Adaptability or versatility
If broad-spectrum CDK inhibition is achieved, then efficacy against multiple CDK isoforms improves, but selectivity for specific diseases may be reduced
Solution Approach 1:
The patent applies universality by designing a pyrazoloquinazoline core structure that can bind to multiple CDK isoforms (CDK1, CDK2, CDK4, CDK6, CDK9). This multi-functional approach allows a single compound to address different cell proliferative diseases caused by various CDK dysregulations
Solution Approach 2:
The patent balances broad-spectrum and disease-specific efficacy by using local quality - placing specific substituents at key positions to maintain affinity for multiple CDK isoforms while creating differential binding characteristics that can be optimized for particular disease indications through selective substitution patterns
Data Source
AI summary
A 1H-pyrazolo[4,3-H]quinazoline compound represented by formula (I) can be used for treating cell proliferation dysfunction, and is an broad-spectrum and strongly-active inhibitor for a cell cyclin-dependent kinase (CDK).